Amphastar (AMPH) Q2 2026 earnings review
New Launches Save the Top Line as Margins Rebound
Amphastar delivered a vital recovery quarter. After a severe margin compression in Q1, gross margins snapped back to 50.8%, reversing the negative narrative. Total revenue grew 5% YoY to $183.9 million, but the composition tells the real story: legacy products and flagship BAQSIMI shrank due to fierce pricing pressures, while the newly launched Ipratropium Bromide ($8.4M) single-handedly kept overall revenue in positive territory. Despite the solid gross profit recovery, heavy operating investments (G&A up 30%) caused GAAP operating income to fall 6% YoY. The company achieved its $175M BAQSIMI annual sales milestone, which will trigger a $100M cash payment to Eli Lilly in Q3.
🐂 Bull Case
The panic from Q1's 41% gross margin appears temporary. Margins bounced back to 50.8%, driven by an accelerating mix shift toward high-margin new launches like Ipratropium, Teriparatide, and Iron Sucrose.
Ipratropium Bromide launched successfully in April and instantly became the primary growth engine, printing $8.4M in its first partial quarter and offsetting legacy portfolio decay.
🐻 Bear Case
Despite unit volumes adding $6.9M, BAQSIMI revenue fell 3% YoY because gross-to-net discounts and pricing concessions subtracted $8.1M. Volume growth is not translating to revenue growth.
Gross profit rose $7M YoY, but total operating expenses surged $9.4M (driven by a 30% jump in both G&A and Selling/Marketing), causing operating income to contract.
⚖️ Verdict: ⚪
Neutral. The business successfully bridged a gap this quarter. The gross margin recovery is highly encouraging, but the structural pricing decay in BAQSIMI and legacy generics means Amphastar must flawlessly execute its new product pipeline just to maintain mid-single-digit growth.
Key Themes
Ipratropium Bromide and New Launches Anchor Growth
With the core portfolio facing headwinds, new product execution is accelerating. Ipratropium Bromide (AMP-007) generated $8.4M following its April launch. Additionally, 'Other products' revenue jumped 25% YoY to $66.2M, driven by recent launches of iron sucrose (+$3.5M) and teriparatide (+$4.5M). Without these three products, overall company revenue would have declined significantly year-over-year.
BAQSIMI Profitability and the $100M Milestone
BAQSIMI's trajectory is reversing from a growth driver to a drag. Q2 sales fell 3% YoY to $45.5M as severe pricing/rebate headwinds (-$8.1M) completely erased the benefits of volume growth (+$6.9M). Despite the revenue contraction, Amphastar still triggered the first annual net sales milestone under the Eli Lilly agreement (trailing contract year sales of $175M), meaning a massive $100M cash payment is due in Q3. This will consume the entirety of the company's YTD operating cash flow ($99.2M).
Legacy Generic Collapse Continues
The structural decay in the legacy portfolio is decelerating the top line. Glucagon sales collapsed 42% YoY to $11.9M due to intense generic competition and the market shift toward ready-to-use alternatives. Epinephrine sales also slipped 2% YoY, primarily due to weakness in the multi-dose vial product. These high-margin legacy cash cows are drying up faster than expected.
Expense Bloat Crushing Operating Income
Amphastar is suffering from negative operating leverage. Selling, distribution, and marketing costs surged 30% YoY to $13.3M (due to freight and BAQSIMI marketing), while G&A jumped 30% YoY to $18.2M (driven by ERP implementation, legal, and personnel costs). R&D also climbed 10% YoY. As a result, GAAP operating income fell from $42.1M in 25Q2 to $39.7M this quarter, completely eroding the $7M gross profit gain.
Other KPIs
Cash generation remains robust, up from $70.7 million in the same six-month period last year. This liquidity is critical as the company prepares to fund the $100 million BAQSIMI milestone payment to Lilly in Q3 without needing to draw on significant debt.
Stable. Revenue declined 8% YoY, but management cited the timing of customer wholesale purchases rather than fundamental weakness, noting that in-store consumer demand continues to show growth. This OTC asset remains highly defensive against generic encroachment.
Guidance
Stable. While management didn't explicitly update the numerical guidance in the Q2 release, they set a 'mid-single digit to high single digit' growth target during the Q1 call. Achieving 5% YoY growth in Q2 suggests they are tracking at the lower end of this range, completely reliant on Ipratropium's continued ramp to offset BAQSIMI pricing issues.
Key Questions
BAQSIMI Pricing Floor
Volume is up, but rebates and pricing concessions erased $8.1M in BAQSIMI revenue this quarter. Has the gross-to-net discount dynamic bottomed out following the May 1st list price increase and the 340B audits?
Capital Allocation Post-Lilly Payment
With the $100 million BAQSIMI milestone payment due to Eli Lilly in Q3, how will this impact your share repurchase velocity and business development appetite for the remainder of 2026?
Ipratropium Exclusivity
Ipratropium Bromide (AMP-007) had a stellar $8.4M launch quarter. Have you seen any signs of an Authorized Generic (AG) entering the market during your 180-day exclusivity window?
G&A Expense Normalization
G&A expenses surged 30% YoY in Q2, driven in part by ERP implementation and legal fees. How much of this increase is one-time in nature versus a new structural run-rate for the business?